Recognized standard
MM23-1st Edition
FDA recognition 7-269 · CLSI · InVitro Diagnostics
Key facts
| Recognition number | 7-269 |
|---|---|
| Designation | MM23-1st Edition |
| Title | Molecular Diagnostic Methods for Solid Tumors (Nonhematological Neoplasms) |
| Standards developer | Clinical Laboratory Standards Institute |
| Specialty area | InVitro Diagnostics |
| Date of entry | Jan 14, 2019 |
| Scope (excerpt) | This guideline covers the current state of molecular diagnostic techniques intended for the characterization of solid tumors, and covers a range of clinical applications including diagnosis, prognosis, therapeutic response prediction for available drugs and those still in clinical trials, as well as… |
At a glance
- None Product codes
- 1–9 FDA guidance documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-recognized consensus standards
The FDA recognizes voluntary consensus standards that manufacturers can cite in premarket submissions to show conformity with specific requirements.
Source: U.S. Food and Drug Administration (FDA), Recognized Consensus Standards database · Source date: